Analyst will focus on phase III studies and travel vaccines in Bavarian report

On Monday, Bavarian Nordic will release its first quarterly report for the year, and a Sydbank analyst is waiting in suspense to hear more about two phase III vaccine studies and how well travel vaccines performed.

Photo: Philip Davali/Ekstra Bladet, Philip Davali

In the year 2022, Bavarian Nordic will be conducting two phase III studies – and investors are keeping a keen eye on news about either, when the biotech firm publicizes figures from its first financial quarterly on Monday.

One of the reasons is that quarter-to-quarter comparisons is made difficult by orders and contracts usually coming in ”batches,” as pointed out by Sydbank Senior Analyst Søren Løntoft Hansen.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs